FIGSFIGS
FIGS
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
817% more call options, than puts
Call options by funds: $12.8M | Put options by funds: $1.4M
0% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]
3.2% less ownership
Funds ownership: 77.61% [Q3] → 74.41% (-3.2%) [Q4]
9% less funds holding
Funds holding: 185 [Q3] → 169 (-16) [Q4]
13% less capital invested
Capital invested by funds: $858M [Q3] → $744M (-$114M) [Q4]
29% less first-time investments, than exits
New positions opened: 30 | Existing positions closed: 42
37% less repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 67
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$7
55%
upside
Avg. target
$7
55%
upside
High target
$7
55%
upside
1 analyst rating
0 positive
0%
1 neutral
100%
0 negative
0%
Telsey Advisory Group Dana Telsey 27% 1-year accuracy 50 / 183 met price target | 55%upside $7 | Market Perform Maintained | 28 Feb 2025 |
Financial journalist opinion
Positive
Seeking Alpha
3 weeks ago
Figs, Inc. - Slow Growth Is Still Growth
Figs, Inc. is undervalued, as strong private equity interest and a robust balance sheet indicate potential for significant returns. Favorable growth trends in healthcare employment and broader market appeal support optimistic revenue projections for Figs, Inc. Derived equity value suggests a 25% upside from the current share price, highlighting market undervaluation post-IPO.
Neutral
Seeking Alpha
4 weeks ago
FIGS Shows Significant U.S. Weakness But Continues To Trade At 50x NOPAT
FIGS, Inc.'s earnings show mixed results, with strong international growth but declining U.S. sales and weak FY25 guidance, raising concerns about profitability and customer acquisition. Despite strong product innovation, FIGS struggles with high marketing costs, poor customer acquisition, and stagnating U.S. sales, making its high valuation unjustifiable. International expansion is promising but comes with lower margins; new management might improve execution, but significant challenges remain.
Positive
Zacks Investment Research
1 month ago
Figs (FIGS) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for Figs (FIGS) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Neutral
Seeking Alpha
1 month ago
FIGS, Inc. (FIGS) Q4 2024 Earnings Call Transcript
FIGS, Inc. (NYSE:FIGS ) Q4 2024 Earnings Conference Call February 27, 2025 5:00 PM ET Company Participants Tom Shaw - Senior Vice President, Investor Relations Trina Spear - Co-Founder & Chief Executive Officer Sarah Oughtred - Chief Financial Officer Conference Call Participants Brooke Roach - Goldman Sachs Brian Nagel - Oppenheimer John Kernan - TD Cowen Dana Telsey - Telsey Group Lorraine Hutchinson - Bank of America Matt Koranda - ROTH Capital Ashley Owens - KeyBanc Capital Markets Nathan Feather - Morgan Stanley Operator Good afternoon, everyone, and thank you for joining today's FIGS Fourth Quarter Fiscal 2024 Earnings Conference Call. My name is Reagan, and I'll be your moderator today.
Positive
Zacks Investment Research
1 month ago
Figs (FIGS) Q4 Earnings Meet Estimates
Figs (FIGS) came out with quarterly earnings of $0.01 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.05 per share a year ago.
Neutral
Business Wire
1 month ago
FIGS Releases Fourth Quarter and Full Year 2024 Financial Results
SANTA MONICA, Calif.--(BUSINESS WIRE)--FIGS, Inc. (NYSE: FIGS) (the “Company”), the global leading healthcare apparel brand dedicated to improving the lives of healthcare professionals, today released its fourth quarter and full year 2024 financial results and published a financial highlights presentation on its investor relations website at ir.wearfigs.com/financials/quarterly-results/. Fourth Quarter 2024 Financial Highlights Net revenues were $151.8 million, an increase of 4.8% year over yea.
Positive
Zacks Investment Research
1 month ago
Countdown to Figs (FIGS) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS
Beyond analysts' top -and-bottom-line estimates for Figs (FIGS), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024.
Neutral
Business Wire
1 month ago
FIGS Announces Participation in the Raymond James 46th Annual Institutional Investors Conference
SANTA MONICA, Calif.--(BUSINESS WIRE)--FIGS, Inc. (NYSE: FIGS), the global leading healthcare apparel brand dedicated to improving the lives of healthcare professionals, today announced that Trina Spear, Chief Executive Officer and Co-Founder, and Sarah Oughtred, Chief Financial Officer, are scheduled to participate in a fireside chat at the Raymond James 46th Annual Institutional Investors Conference on Monday, March 3, 2025, at 11:00 a.m. ET. The audio portion of the fireside chat will be web.
Neutral
Business Wire
1 month ago
FIGS Announces Date of Fourth Quarter and Full Year 2024 Earnings Release, Conference Call and Webcast
SANTA MONICA, Calif.--(BUSINESS WIRE)--FIGS, Inc. (NYSE: FIGS), the global leading healthcare apparel brand dedicated to improving the lives of healthcare professionals, today announced it will release its fourth quarter and full year 2024 financial results on Thursday, February 27, 2025, after U.S. markets close. FIGS management will host a conference call that day at 2:00 p.m. PT / 5:00 p.m. ET to discuss its financial and business results and outlook. Prior to the call, FIGS will publish a f.
Negative
Reuters
2 months ago
Scrubs maker Figs rebuffs Story3 Capital's take-private offer
Figs said on Thursday it has rebuffed private equity firm Story3 Capital Partners' offer to acquire the scrubs maker.
Charts implemented using Lightweight Charts™